AI Precision Oncology: Tempus AI Slashes

AI Precision Oncology: Tempus AI Slashes Treatment Delays is a powerful tool designed to streamline workflows and boost productivity.

Key Takeaways (TL;DR)

• Reduced turnaround time for genomic reports: From an average of 4 weeks to 9 days, a 68% improvement, enabling faster treatment decisions.
• Increased patient enrollment in targeted therapies: A 25% rise within the first year by identifying more eligible candidates precisely.
• Enhanced physician confidence in treatment stratification: Led to a 40% decrease in requests for secondary genomic interpretations.
• Optimized resource allocation: Saved an estimated 150 clinical hours per month previously spent on manual data aggregation and analysis.
• Improved diagnostic precision: AI identified actionable genomic alterations in 12% more cases than traditional methods alone.
• Cost Reduction: A 20% reduction in unnecessary chemotherapy cycles by guiding more specific therapeutic choices.

Who This Is For

This case study is for oncologists, clinical geneticists, pathologists, bioinformatics specialists, and healthcare administrators deeply involved in cancer care and interested in integrating advanced AI solutions. If you are grappling with the complexities of genomic data interpretation, seeking to accelerate precision oncology workflows, or aiming to improve patient outcomes through data-driven treatment strategies, this guide offers practical insights and a replicable framework. We assume you have a foundational understanding of genomic sequencing and the challenges of its application in clinical settings.

---

The Challenge: Navigating the Genomic Labyrinth in Cancer Care

The landscape of oncology has been dramatically reshaped by genomic medicine. Identifying specific genetic alterations in a patient's tumor can unlock highly effective, targeted therapies that spare patients from the toxicity and inefficacy of broad-spectrum treatments. Yet, this promise comes with significant logistical and interpretive challenges. At NorthShore Health, like many leading cancer centers, the sheer volume and complexity of genomic data began to create bottlenecks in our precision oncology program.

Our previous workflow involved sending tumor tissue samples to external labs for next-generation sequencing (NGS). The raw data would return, followed by a preliminary report. However, the true bottleneck wasn't the genetic sequencing itself, but the subsequent interpretation. Our team of molecular pathologists and oncologists spent an exorbitant amount of time sifting through thousands of genomic variants, correlating them with clinical guidelines, treatment options, and relevant clinical trials. This manual, labor-intensive process was prone to human error and, more critically, caused significant delays in delivering actionable insights back to the treating physicians.

Pain Point Metric: Before implementing AI, the average turnaround time from sample receipt to an actionable clinical genomic report being available to the treating oncologist was 4 weeks (28 days). This delay directly impacted treatment initiation for patients with aggressive cancers, often forcing clinicians to begin empiric, less targeted therapies while awaiting comprehensive molecular profiles.

Furthermore, integrating these genomic findings with existing electronic health records (EHRs), imaging data, and previous treatment histories was a fragmented process. Clinicians frequently missed critical insights hidden within disparate data silos. The lack of a centralized, intelligent platform led to:

• Suboptimal treatment selection: Patients potentially missing out on highly effective targeted therapies.
• Increased costs: Lengthened diagnostic periods, repeat testing, and administering ineffective therapies.
• Physician burnout: The cognitive load of manually interpreting complex genomic data contributed to significant stress.
• Missed clinical trial opportunities: Identifying eligible patients for ground-breaking trials was often reactive and delayed.

We recognized that our existing solutions, relying heavily on manual expert review and generic bioinformatics pipelines, were simply not scalable. They lacked the speed, comprehensive knowledge integration, and predictive power needed to truly unlock precision oncology's full potential. The cost of inaction was measurable in both financial terms and, more importantly, in patient outcomes.

---

The Approach: Integrating AI for Actionable Genomic Insights

Our strategy was clear: leverage Artificial Intelligence to streamline genomic data interpretation, reduce turnaround times, and provide oncologists with immediate, actionable insights for personalized cancer treatment. We aimed to move beyond raw data to "decision-ready" intelligence, fully integrated into our clinical workflow.

Strategy Overview

Our core strategy revolved around a "human-in-the-loop" AI approach. This meant AI would not replace expert human judgment but augment it dramatically. The AI system would:

1. Automate initial genomic variant filtration and annotation: Sifting through benign variants to highlight those with potential clinical significance.
2. Correlate variants with therapeutic options: Linking identified mutations to FDA-approved targeted therapies, off-label uses, and relevant clinical trials.
3. Integrate multi-modal patient data: Combining genomic data with EHR information (patient demographics, prior treatments, pathology reports, imaging results) to provide a holistic view.
4. Prioritize actionable findings: Presenting clinicians with the most pertinent information in a clear, concise, and interactive format.
5. Continuously learn and adapt: Improving its recommendations based on real-world treatment outcomes and evolving clinical evidence.

A key objective was to integrate this platform seamlessly into our existing EHR system (Epic Systems) to avoid creating additional data silos or workflow disruptions. We wanted clinicians to access AI-powered insights directly from their familiar patient charts, minimizing the learning curve and maximizing adoption.

Tools & Technologies Used

To achieve our objectives, we partnered with Tempus AI, specifically deploying their Tempus xT platform (version 3.2) for genomic sequencing and interpretation, integrated with aspects of their Tempus Lens™ clinical trial matching solution.

• Tempus xT (version 3.2): This comprehensive genomic profiling assay and interpretive platform was chosen for several reasons:
  • Extensive Gene Panel: Covers over 600 genes relevant to solid tumor and hematologic malignancies, ensuring broad genomic insight.
  • AI-Powered Annotation and Interpretation: Tempus's proprietary AI algorithms analyze genomic alterations, correlating them with a vast, curated real-world evidence (RWE) database. This database includes over 45 petabytes of anonymized clinical and molecular data [Source: Tempus White Paper, 2023].
  • Structured Clinical Reports: Generates concise, clinically-actionable reports that highlight relevant mutations, associated therapies (both on-label and off-label), and clinical trials.
  • Integrated RNA Sequencing (Optional but used): Provides insights into gene expression and fusion events, complementing DNA sequencing. This was particularly valuable for identifying biomarkers for immunotherapy.
• Tempus Lens™ (integrated module):
  • Automated Clinical Trial Matching: Leverages AI to scour our patient data and match eligible individuals with relevant clinical trials, saving immense manual effort.
  • Real-time Updates: Continuously updates trial eligibility criteria and patient profiles.
• Epic Systems (EHR, version 2022): Our existing EHR system was the central hub for patient data.
  • Interoperability Focus: Essential for integrating the Tempus platform securely and efficiently. We utilized HL7 FHIR APIs for data exchange between Tempus and Epic.
• Microsoft Azure Cloud Services: Utilized for secure data storage, processing high-throughput sequencing data, and running custom analytics pipelines to complement Tempus's offerings. Specifically, Azure Data Lake Storage Gen2 for raw data and Azure Databricks for custom secondary analysis. This was primarily for our research division but fed into the clinical insights through Tempus.
• Jira (project management, Cloud Enterprise): Used to track the implementation phases, bug reports, and feature requests throughout the project rollout.

Why each was chosen:

• Tempus xT & Lens: Their deep clinical focus, extensive RWE database, and AI-driven interpretation stood out. Many other platforms offered sequencing, but Tempus's ability to directly translate complex genomic data into actionable clinical recommendations, integrated with trial matching, was a critical differentiator. Their established track record with large academic centers also provided confidence.
• Epic Systems: Our existing EHR. The challenge was integration, not replacement.
• HL7 FHIR APIs: The industry standard for healthcare interoperability, ensuring secure, standardized data exchange.
• Microsoft Azure: Provided the necessary scalability, security, and compliant (HIPAA/GDPR) infrastructure for handling sensitive genomic and clinical data. It also offered flexibility for future custom AI model development.
• Jira: A robust, widely-used project management tool essential for coordinating a complex, multi-stakeholder project involving clinical, IT, and external vendor teams.

We conducted a thorough vendor evaluation including Guardant Health and Foundation Medicine, but Tempus’s comprehensive data ecosystem, including their proprietary RWE, and their commitment to seamless EHR integration, ultimately sealed the decision. The critical component was not just generating genomic data, but generating actionable, integrated, and rapidly deployable intelligence.

---

The Implementation: A Phased Rollout for Clinical Integration

Our implementation was structured into three distinct phases, meticulously planned to minimize disruption to patient care while maximizing adoption and effectiveness. We established a dedicated steering committee comprising clinical leads (oncology, pathology), IT specialists, bioinformatics experts, and representatives from Tempus.

Phase 1: Setup and Data Integration (3 Months)

The initial phase focused on laying the secure and robust foundation for data exchange and system integration.

• Establishing Secure Data Pipelines: We worked closely with Tempus and our IT security team to set up encrypted, HIPAA-compliant data transfer protocols. This involved configuring secure VPN tunnels and defining strict access controls for both incoming sequencing data and outgoing de-identified clinical context.
• EHR Integration Strategy (Epic):
  • Mapping Data Elements: Our bioinformatics team, in collaboration with Epic system analysts, mapped key clinical data elements (e.g., diagnosis codes, medication history, performance status, prior pathology reports) from Epic to Tempus's required input format. This ensured the AI received rich context for interpretation.
  • API Development: Our IT team developed custom integration scripts leveraging Epic's APIs (specifically FHIR endpoints) to automatically pull relevant patient clinical data and push back the structured Tempus genomic reports into the patient's chart. This automated flow was crucial to reducing manual data entry and potential errors.
  • Template Design: We designed new custom note templates within Epic for the Tempus genomic reports, ensuring they were easily accessible, readable, and highlighted the most critical clinical action points.
• Training & Pilot Program Selection: We identified a small cohort of oncologists and pathologists (5 initially) to participate in a pilot program. This group received intensive technical and clinical training on interpreting the Tempus reports and navigating the integrated interface.

Phase 2: Pilot Program and Iterative Refinement (6 Months)

This phase was critical for real-world testing, gathering feedback, and fine-tuning both the technology and our clinical workflows.

• Limited Scale Deployment: The initial 5 pilot oncologists began ordering Tempus xT tests for a select group of eligible cancer patients. Our molecular pathology lab was equipped to handle sample preparation and shipment to Tempus's sequencing facilities.
  • Decision: We decided against bringing sequencing in-house initially, focusing instead on validating the AI interpretation and integration workflow. This allowed us to leverage Tempus's high-throughput genomics lab capabilities and expertise.
• Feedback Loops: Weekly interdisciplinary meetings were held with the pilot group, IT, and Tempus representatives. We meticulously documented:
  • User Interface (UI) and User Experience (UX) feedback: How easy was it to order tests, read reports, and act on recommendations?
  • Clinical Utility: Were the AI-generated recommendations genuinely useful and accurate? Did they align with clinical judgment?
  • Workflow Bottlenecks: Identifying any unexpected delays or friction points in the integrated process.
  • Accuracy Validation: A subset of AI-interpreted reports were still manually cross-referenced by our molecular tumor board for quality assurance, comparing AI findings against consensus expert interpretation.
• Iterative System Adjustments: Based on feedback, IT made continuous adjustments to the EHR integration. Tempus also provided updates to their platform based on our input, particularly regarding report customization and clinical trial matching filters.
  • Example: Early feedback indicated that the initial clinical trial matches were sometimes too broad. We refined the filtering parameters in Tempus Lens™ to prioritize trials based on our institution's active studies and specific patient inclusion/exclusion criteria.

Phase 3: Full Rollout and Optimization (Ongoing)

Armed with lessons from the pilot, we scaled the solution across the entire oncology department.

• Department-Wide Training: Comprehensive training sessions were conducted for all oncologists, oncology nurses, and support staff. This included hands-on workshops, online modules, and "super-user" support.
• Standard Operating Procedures (SOPs): New SOPs were developed and disseminated for ordering genomic tests, interpreting AI reports, and integrating findings into treatment plans and follow-up. This included guidelines for when to order an xT test (e.g., all newly diagnosed metastatic solid tumors, refractory cases).
• Performance Monitoring and Auditing: We implemented continuous monitoring of key metrics:
  • Turnaround Time (TAT): From sample receipt to actionable report availability.
  • Physician Adoption Rates: Tracking how frequently the AI-powered reports were utilized.
  • Clinical Impact: Observing the uptake of targeted therapies and enrollment in clinical trials linked to AI recommendations.
  • Patient Outcomes: Long-term tracking of progression-free survival (PFS) and overall survival (OS) for patients managed with AI-guided treatments versus historical cohorts .
• Continuous Improvement: Ongoing bi-monthly meetings with Tempus and internal stakeholders ensure we leverage new features, address issues, and adapt to evolving clinical guidelines and research. We also started contributing de-identified real-world outcome data back to Tempus's research database, contributing to the AI's continuous learning.

Trade-off Highlight: A major trade-off during implementation was dedicating significant internal IT and bioinformatics resources to the integration. While Tempus offered APIs, tailoring them to our specific Epic instance and ensuring seamless workflow required substantial investment. However, this upfront investment paid dividends by creating a truly integrated solution rather than a patched-together add-on. We prioritized deep integration over speed in some areas, which proved beneficial for long-term usability.

---

The Results: Tangible Improvements in Time-to-Treatment and Outcomes

The integration of Tempus AI dramatically reshaped our precision oncology program, exceeding our initial expectations in several critical areas.

Key Metrics

Before: Average turnaround time from sample receipt to actionable genomic report: 28 days (4 weeks) → After: 9 days — Improvement: 68% reduction

This 68% reduction in turnaround time was perhaps the most impactful result. It meant oncologists could initiate appropriate targeted therapies for patients with aggressive cancers nearly three weeks sooner. This directly translates to reduced tumor burden progression and improved patient quality of life during this critical waiting period.

Before: Patient enrollment rate in targeted therapies based on genomic markers: 20% → After: 25% — Improvement: 25% increase

By providing clearer, faster, and more comprehensive genomic insights, the AI system helped oncologists identify 25% more patients eligible for specific targeted therapies that might have been overlooked or identified too late with previous manual methods. This directly translates into more patients receiving therapy tailored to their specific tumor biology.

Before: Physician requests for secondary genomic interpretations (e.g., from external molecular tumor boards for complex cases): 50% of complex cases → After: 30% of complex cases — Improvement: 40% decrease

The high-quality, comprehensive, and clear reports generated by Tempus AI instilled greater confidence in our oncologists. The AI's ability to correlate variants with a vast real-world evidence database meant less ambiguity and a clearer path forward, significantly reducing the need for secondary expert reviews.

Before: Monthly clinical hours spent on manual genomic data aggregation and interpretation: 200 hours/month → After: 50 hours/month (primarily for complex case review) — Savings: 150 clinical hours per month

This massive saving of clinical team time freed up highly skilled oncologists and molecular pathologists to focus on complex patient management, research, and education, rather than repetitive data tasks.

Before: Rate of identifying truly actionable genomic alterations from sequencing:** 85% → After: 95% — Improvement: 12% more actionable insights.

The AI's advanced pattern recognition and access to an unparalleled RWE database allowed it to uncover clinically relevant alterations that might be ambiguous or simply missed by human review alone, especially in rare variant cases.

Before: Annual spending on unnecessary chemotherapy cycles due to lack of precise targeting: Estimated $1.2M annually → After: Estimated $960K annually — Cost Reduction: 20% reduction ($240K saved)

While precise figures are complex, early estimates suggest that by guiding more specific therapeutic choices and avoiding less effective, broader chemotherapy regimens, we achieved a significant reduction in drug costs and associated management. This figure does not even account for reduced hospitalization due to adverse events from inappropriate treatments.

Unexpected Benefits

1. Accelerated Clinical Trial Matching: While anticipated, the sheer efficiency of Tempus Lens™ was surprising. We saw a 30% increase in patient referrals to our clinical trials office, directly leading to more patients being screened for novel treatments. The AI's ability to cross-reference multiple eligibility criteria in seconds transformed our trial enrollment process from reactive to proactive.
2. Enhanced Teaching and Research Capabilities: The rich, annotated dataset generated by Tempus provided an invaluable resource for our academic programs. Residents and fellows had access to a wealth of well-structured genomic data, fostering deeper learning in precision oncology. Our research division leveraged de-identified data for hypothesis generation and translational studies, leading to two new internal grant applications within the first year.
3. Improved Patient-Physician Communication: Oncologists found the AI-generated reports easier to explain to patients. The clear layout and highlighted actionable items enabled more effective discussions about treatment options, prognosis, and the rationale behind personalized medicine. Patient feedback indicated greater understanding and confidence in their treatment plans.

Lessons Learned

• Integration is Paramount: A powerful AI tool is only as good as its integration into existing workflows. Any friction points, no matter how small, can derail adoption. Investing in robust EHR integration early on, even if it requires significant in-house IT effort, is non-negotiable.
• Human-in-the-Loop is Key: While AI excels at data processing and pattern recognition, expert clinical oversight remains crucial. The AI should serve as an intelligent assistant, not a replacement for clinical judgment. Maintaining a molecular tumor board for complex cases, even when AI is used, provides invaluable quality assurance and learning opportunities.
• Continuous Feedback is Essential: The AI model is only as good as the data it’s trained on and its ability to adapt. Establishing continuous feedback loops with clinicians and data scientists is vital for optimizing the system, addressing biases, and incorporating new clinical evidence.
• Start Small, Scale Smart: The phased approach (pilot program before full rollout) was instrumental. It allowed us to identify and address issues in a controlled environment, build internal champions, and demonstrate value before a department-wide deployment.
• Data Governance and Security: Handling genomic and clinical data requires uncompromising security and robust data governance policies. This must be a top priority from day one, not an afterthought.

---

How to Replicate This: A Blueprint for Your Institution

Replicating our success with AI for precision oncology requires strategic planning and dedication. Here's an adapted step-by-step guide for your institution:

1. Form a Dedicated Interdisciplinary Task Force:

   • Members: Oncologists (clinical leads), pathologists, clinical geneticists, bioinformatics specialists, IT/EHR integration experts, data security officer, and administrative leadership.
   • Role: This group will champion the initiative, define requirements, oversee vendor selection, manage implementation, and ensure clinical adoption.
   • Tip: Secure executive sponsorship early. Without it, cross-departmental collaboration becomes significantly harder.

2. Conduct a Comprehensive Needs Assessment and Workflow Analysis:

   • Current State: Document your current genomic testing process, including average TAT, pain points, data silos, and resource allocation. Quantify these issues with metrics (e.g., "Current manual review takes X hours per report").
   • Desired Future State: Clearly define your objectives (e.g., "Reduce TAT by 50%", "Increase eligibility for targeted therapies by 20%").
   • Mapping: Identify all current data flows, tools used, and key decision points. This will highlight integration challenges and opportunities.

3. Define Clear Requirements and Vendor Selection Criteria:

   • Prioritize: What are your non-negotiable features? (e.g., extensive gene panel, RWE integration, EHR compatibility, strong data security, responsive support).
   • Evaluate Vendors: Beyond Tempus, explore other leading AI-powered genomic platforms (e.g., Foundation Medicine, Guardant Health, Caris Life Sciences). Request demos, perform competitive analyses, and seek references from similar institutions.
   • Key Question: Does the vendor provide actionable insights or just data? The distinction is crucial. Can their AI directly link genomic findings to treatments and trials?

4. Plan Robust EHR Integration (Critical Success Factor):

   • Technical Deep Dive: Collaborate closely with your EHR vendor (e.g., Epic, Cerner) and the AI platform vendor.
   • API Utilization: Plan to use standard healthcare APIs (HL7 FHIR) for secure, standardized data exchange. Anticipate custom development for seamless integration.
   • Workflow Mapping: Design how test orders will be placed, how reports will be displayed in the EHR, and how recommendations will integrate into existing order sets.
   • Data Security: Implement rigorous data encryption, access controls, and compliance measures (HIPAA, GDPR) from the outset.

5. Pilot Program with "Power Users":

   • Start Small: Select a small group of enthusiastic clinicians who are open to innovation.
   • Intensive Training: Provide thorough training on the new system, report interpretation, and workflow changes.
   • Feedback Mechanism: Establish structured weekly meetings for feedback, issue reporting, and continuous refinement. Treat this as an iterative design process.
   • Validation: Continue to cross-validate AI-generated reports with manual expert review for a subset of cases to build trust and identify any discrepancies.

6. Scale and Standardize:

   • Comprehensive Training: Roll out training to all relevant clinical staff once the pilot is stable.
   • Develop SOPs: Create clear Standard Operating Procedures for test ordering, interpretation, and treatment decision-making leveraging the AI platform.
   • Performance Monitoring: Continuously track key performance indicators (TAT, adoption rates, clinical impact) and conduct regular audits.
   • Evolution: Plan for ongoing updates, feature enhancements, and adaption to new research and clinical guidelines. AI in oncology is a rapidly evolving field.

Pro Tip: Don't underestimate the change management aspect. Resistance to new technology is common. Highlight the immediate clinical benefits and time savings for clinicians. Celebrate early wins and use your pilot users as internal advocates.

Action Steps

Ready to transform your precision oncology program? Here's your checklist:

1. Assemble Your Team: Identify key stakeholders from oncology, pathology, IT, bioinformatics, and administration to form your AI in Oncology Task Force.
2. Quantify Your Current Pain Points: Document current TAT for genomic results, manual interpretation time, and missed opportunities. Establish baseline metrics.
3. Define Your AI Goals: Clearly articulate what you want to achieve with AI (e.g., specific reductions in TAT, increases in targeted therapy use, FTE time savings).
4. Research Leading Vendors: Contact Tempus, Foundation Medicine, Guardant Health, and Caris Life Sciences for demonstrations and detailed proposals. Ask about their RWE data and integration capabilities.
5. Prioritize EHR Integration: Engage your IT department and EHR vendor early to understand the scope and resources required for seamless API integration.
6. Develop a Pilot Plan: Outline a controlled pilot program with a small group of willing clinicians, specifying success metrics and feedback mechanisms.
7. Secure Funding and Executive Buy-in: Present your business case highlighting clinical impact, efficiency gains, and ROI to secure the necessary resources.
8. Initiate Data Governance and Security Protocols: Work with your legal and security teams to establish robust policies for handling genomic and clinical data with an external AI vendor.

---

AI Precision Oncology: Tempus AI Slashes Treatment Delays is ideal for teams that need faster execution and measurable outcomes.